Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy study of nemolizumab in moderate-to-severe atopic dermatitis
NL-OMON60056Phase 3Completed
- Sponsor
- Galderma
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nemolizumab in atopic dermatitis (AD), sponsored by Galderma. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Incidence of serious treatment-emergent adverse events and 1 more. Started Jun 2021; status: completed.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON60056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60056.